by The global brucellosis vaccines market size was estimated at USD 242.70 million in 2023 and is anticipated to reach around USD 389.50 million by 2033 growing at a CAGR of 4.84% from 2024 to 2033.
Key Points
- The North America brucellosis vaccines market size reached USD 104.36 million in 2023 and is expected to surpass around USD 167.49 million by 2033.
- North America has dominated the market with revenue share of 43% in 2023.
- By application, in 2023, the cattle segment has accounted 57% revenue share in 2023.
- By type, the RB51 vaccine segment dominated the market with revenue share of 43% in 2023.
- By Vaccine Type, the DNA Vaccines segment has captured 32.5% revenue share in 2023.
- By distribution channel, the public segment had the largest market share in 2023.
The Brucellosis Vaccines Market refers to the segment of the pharmaceutical industry dedicated to the development, production, and distribution of vaccines aimed at preventing brucellosis, a bacterial infection caused by various species of Brucella bacteria. Brucellosis primarily affects animals, but it can also be transmitted to humans through direct contact with infected animals or consumption of contaminated animal products. Vaccination plays a crucial role in controlling the spread of brucellosis, especially in livestock populations, where the disease can cause significant economic losses.
Get a Sample: https://www.precedenceresearch.com/sample/4113
Growth Factors:
Several factors contribute to the growth of the Brucellosis Vaccines Market. These include the increasing demand for brucellosis prevention in livestock to ensure food safety and security. Additionally, rising awareness about zoonotic diseases and the importance of vaccination among veterinarians, livestock farmers, and regulatory authorities further drives market growth. Technological advancements in vaccine development and manufacturing processes also facilitate the expansion of the market by enhancing vaccine efficacy and safety.
Region Insights:
The Brucellosis Vaccines Market exhibits regional variations influenced by factors such as the prevalence of brucellosis in animal populations, economic development, government regulations, and healthcare infrastructure. Regions with high livestock populations, such as Asia-Pacific, Latin America, and Africa, typically have significant market demand due to the need for effective disease control measures. Additionally, regions with a history of brucellosis outbreaks may prioritize vaccination programs, contributing to market growth.
Brucellosis Vaccines Market Scope
| Report Coverage | Details |
| Global Market Size in 2023 | USD 242.70 Million |
| Global Market Size in 2024 | USD 254.46 Million |
| Global Market Size by 2033 | USD 389.50 Million |
| Growth Rate from 2024 to 2033 | CAGR of 4.84% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type, By Vaccine, By Application, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Brucellosis Vaccines Market Dynamics
Drivers:
Key drivers of the Brucellosis Vaccines Market include government initiatives to control zoonotic diseases, increasing investments in veterinary healthcare infrastructure, and growing awareness about the economic impact of brucellosis on agriculture. Furthermore, the emergence of new strains of Brucella bacteria and the potential for bioterrorism involving these pathogens underscore the importance of vaccination as a preventive measure, driving market demand.
Opportunities:
Opportunities in the Brucellosis Vaccines Market abound, particularly in the development of improved vaccines with enhanced efficacy, safety, and ease of administration. Collaborations between pharmaceutical companies, research institutions, and government agencies can facilitate the discovery and development of novel vaccine candidates. Additionally, expanding market access through partnerships with veterinary clinics, animal health organizations, and government vaccination programs presents lucrative opportunities for market players.
Challenges:
Despite the growth prospects, the Brucellosis Vaccines Market faces several challenges. These include the complex nature of Brucella bacteria, which can evade the host immune response and pose challenges for vaccine development. Regulatory hurdles related to vaccine approval and registration processes, particularly in different regions with varying standards, can also impede market growth. Moreover, limited awareness among stakeholders about the importance of brucellosis vaccination and budget constraints in resource-limited settings pose challenges to market penetration and uptake of vaccines.
Read Also: Dental Caries Treatment Market Size to Rake USD 11.60 Bn by 2033
Brucellosis Vaccines Market Recent Developments
- In March 2024, Boehringer Ingelheim, a renowned player in the animal health sector, collaborated with Square Pharmaceuticals to launch Aftovaxpur in Bangladesh. This advanced foot-and-mouth disease (FMD) vaccine is specifically formulated for ruminants, including cattle and sheep, aiming to enhance livestock health in the region.
- In October 2023, Zoetis, a leading animal health company based in the US, made headlines by acquiring Semex, a Canadian company specializing in bovine genetics and reproductive technology. This strategic move aims to bolster Zoetis’ standing in the cattle health market, particularly by enhancing its brucellosis vaccine offerings. The acquisition brings valuable expertise and a robust distribution network from Semex, strengthening Zoetis’ position in cattle breeding management.
- In April 2023, Cornell University College of Veterinary Medicine (CVM) scientists researched and developed a novel diagnostic test to identify Brucella canis. This test helps in the early diagnosis of this zoonotic disease, which can spread to humans through contact with infected dogs. This will boost vaccination over time.
- In July 2023, A notable development came from Hester Biosciences, an animal health company in India, with the launch of a new oral brucellosis vaccine for cattle. This innovative vaccine, based on the Brucella Abortus B19 strain, offers a more convenient and potentially cost-effective alternative to traditional injection-based vaccines. The introduction of this oral vaccine could open up new market segments, particularly in regions with limited resources, such as India.
Brucellosis Vaccines Market Companies
- Merck & Co.
- CZ Vaccines
- Colorado Serum Company
- Indian Immunologicals
- Hester Biosciences
- Veterinary Technologies Corporation
- Laboratorios Tornel
- Five Animal Health
- VETAL Animal Health Products Inc.
Segments Covered in the Report
By Type
- Rbs1 Vaccine
- S19 Vaccine
- Others
By Vaccine
- DNA Vaccine
- Subunit Vaccine
- Vector Vaccine
- Recombinant Vaccine
By Application
- Cattle
- Sheep & Goat
- Others
By Distribution Channel
- Veterinary Hospitals & Clinics
- Retail Channels
- Public
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
